Начало・Списък с акции・Vir Biotechnology Inc

Vir Biotechnology Inc

Затворен

СекторЗдравеопазване

9.19 2.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.92

Максимум

9.19

Ключови измерители
By Trading Economics
Приходи	80M -46M
Продажби	239M 239M
EPS	0.47
Марж на печалбата	-19.09
Служители	367
EBITDA	201M 78M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+136.56% upside

Дивиденти
By Acuity
Следващи печалби	4.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.3M 1.5B
Предишно отваряне	6.97
Предишно затваряне	9.19

Настроения в новините

By Acuity

20%

80%

46 / 340 Класиране в Healthcare

Vir Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.08.2026 г., 19:36 ч. UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

10.08.2026 г., 23:56 ч. UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

7.08.2026 г., 19:36 ч. UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

6.08.2026 г., 23:21 ч. UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

5.08.2026 г., 23:41 ч. UTC

News

Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

3.08.2026 г., 19:46 ч. UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

30.07.2026 г., 19:58 ч. UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

29.07.2026 г., 19:27 ч. UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

28.07.2026 г., 15:46 ч. UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27.07.2026 г., 20:07 ч. UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25.07.2026 г., 00:01 ч. UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24.07.2026 г., 23:31 ч. UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21.07.2026 г., 17:16 ч. UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20.07.2026 г., 21:02 ч. UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Сравнение с други в отрасъла

Ценова промяна

Vir Biotechnology Inc Прогноза

Ценова цел

By TipRanks

136.56% нагоре

12-месечна прогноза

Среден 21.29 USD 136.56%

Висок 30 USD

Нисък 15 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Vir Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Vir Biotechnology Inc през последните 3 месеца.

Настроение

By Acuity

46 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.